Pharmacelera key facts
as of Oct 2026- Developer of a drug discovery platform designed to explore large and diverse chemical spaces.
- Pharmacelera is valued at approximately $9.2M as of Oct 2026 (last reported valuation).
- It has raised $9.0M; the latest was Later Stage VC ($7.1M) in Feb 2026.
- Notable investors include European Innovation Council, Inveready Asset Management, General Inception, Clave Capital, AVANÇSA — 11 tracked in total.
- Status: Privately Held (backing).
Pharmacelera's last reported valuation, May 2021. Nothing priced has surfaced since.
- ·The complete investor list: 11 names
- ·Watch Pharmacelera: the Monday email on marks, rounds and moves
Pharmacelera funding rounds
No funding rounds for Pharmacelera are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Pharmacelera
11+Pharmacelera valuation
Pharmacelera's last reported valuation was $9.2 million in May 2021. No priced round, secondary trade or fund mark has surfaced since.
Pharmacelera investors
11 investors are on record for Pharmacelera, including European Innovation Council, Inveready Asset Management, General Inception and Clave Capital.
About Pharmacelera
Developer of a drug discovery platform designed to explore large and diverse chemical spaces. The company's platform uses a 3D representation of molecules based on electrostatic, steric and hydrophobic interaction fields derived from semi-empirical quantum-mechanics calculations, enabling bioinformaticians and medicinal chemists to obtain results using benchmarked technology and boost their drug discovery projects.
- Sector
- Healthcare
- HQ
- Barcelona, Spain
- Founded
- 2011
- Employees
- 24
- Website
- pharmacelera.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.